Abstract: The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.
Type:
Grant
Filed:
March 27, 2018
Date of Patent:
May 7, 2019
Assignees:
ATOX BIO LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
Inventors:
Raymond Kaempfer, Anat Shirvan, Gila Arad
Abstract: The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.
Type:
Grant
Filed:
December 7, 2014
Date of Patent:
May 8, 2018
Assignees:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD, ATOX BIO LTD.
Inventors:
Raymond Kaempfer, Anat Shirvan, Gila Arad
Abstract: Disclosed are peptides and methods for the treatment of bacterial infections and associated inflammation. Effective doses and treatment protocols are disclosed.
Type:
Grant
Filed:
January 16, 2013
Date of Patent:
February 14, 2017
Assignee:
ATOX BIO LTD.
Inventors:
Anat Shirvan, Dan Teleman, Gila Arad, Raymond Kaempfer